Food Neutraceuticals ingredients
Catch a liability before it's in a formulation
A novel ingredient that fails toxicology after three months of formulation work is a far more expensive problem than the same finding two weeks in. Biobide's GLP-certified environmental and systemic safety data covers food ingredients directly, alongside the standard genotoxicity battery ingredient dossiers are assessed against — so the finding lands at the ingredient stage, not the product stage.
Selected clients in this space: DSM-Firmenich
Why formulation teams screen upstream
Cheap to find early, expensive to find late
Systemic screening before formulation locks in
Developmental, hepatic and neuro endpoints get flagged while the ingredient is still easy to swap out, not after three rounds of sensory testing.
A genotoxicity package regulators already recognize
Ames, micronucleus and chromosomal aberration testing sit inside the same core battery food ingredient dossiers are typically assessed against.
GLP where the submission needs it
Results come out of a GLP-certified environment built specifically for regulatory-grade data, not repurposed from an internal screening run.
Parallel dose-ranges, one plate format
24- and 96-well compatibility means testing multiple concentrations or formulation variants doesn't multiply your timeline.
Relevant from the catalogue
Assays this industry books most
The core battery food and nutraceutical ingredient dossiers pull from the catalogue.
Regulatory context
The battery is structured to support food ingredient and nutraceutical safety dossiers that require systemic toxicology and standard genotoxicity data ahead of submission.
Bringing a new ingredient to market
Send the formulation details and intended use level, and we'll scope a safety battery against your submission timeline.
